[{"blogurl": "http://www.ask-cato.com\n", "blogroll": [], "title": "Ask Cato"}, {"content": ["Studies of drugs, biologics or devices that are intended for use in pediatric populations fall under far more stringent guidelines than those intended for use in adults. \u00a0The issues with pediatric studies range from informed consent concerns to stricter risk-to-benefit \u2026 Continue reading \u2192 The post Considerations for the Assessment of Pain in Non-Verbal and Pediatric Subjects appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/1OkZI6wFjAw/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["On 25 September 2012, three lots of steroid injections intended to treat pain were recalled by the pharmaceutical compounding company New England Compounding Center (NECC) in Framingham, MA, because of fungal contamination.\u00a0 By Thursday, 11 October 2012, 12 people had \u2026 Continue reading \u2192 The post Meningitis Tragedy Leads to Calls for Increased FDA Oversight appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/TcN2NKK_tYM/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["On 26 September 2012, a notice was published in the Federal Register that the Department of Health and Human Services was transferring responsibility to the FDA for ensuring that clinical trial data is appropriately submitted to Clinical Trial Registry and \u2026 Continue reading \u2192 The post Clinical Trial Reporting appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/LHL8MDkI5uw/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["There were only a few guidances released by FDA in September 2012: Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products Final Guidance for Industry: Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion Complicated \u2026 Continue reading \u2192 The post New FDA Guidances from September 2012 appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/aVddsHy6ptk/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["The FDA is looking to mandate electronic submissions in the next few years. At the same time, they and other regulators are looking to upgrade the eCTD standard. Why would the FDA mandate electronic submissions and change the standard at \u2026 Continue reading \u2192 The post Updated: Free Educational Webinar \u2013 Regulatory Electronic Submissions: eCTD v4 Background and Drivers appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/cx5iq3Vl64E/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["The recently passed FDA Safety and Innovation Act makes major changes to the de novo reclassification process for medical devices.\u00a0 Namely, the new law mandates that a manufacturer can simply submit a request to the FDA for de novo classification \u2026 Continue reading \u2192 The post De novo device reclassification: What have you done for me lately? appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/8Bufg-aB6LY/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["It\u2019s been a slow summer at FDA, with only four new guidances issued in the month of August 2012: Draft Guidance for Industry: Self-Identification of Generic Drug Facilities, Sites, and Organizations Draft Guidance for Industry: Self-Identification of Generic Drug Facilities, \u2026 Continue reading \u2192 The post New Guidances Released by FDA in August 2012 appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/VS2lhbQ79uY/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["The 06 August 2012 announcement by researchers from Boston\u2019s Brigham and Women\u2019s Hospital reporting the identification of a blood biomarker that could lead to earlier diagnoses and perhaps an actual treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig\u2019s disease, \u2026 Continue reading \u2192 The post Biomarkers: Where are We Today? appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/JrkNdnXdrJk/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.\u00a0 In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: \u2026 Continue reading \u2192 The post FDASIA, Part 4: Drug Supply Chain, Drug Shortages, and Other Provisions appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/0g9MNI7hD4M/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}, {"content": ["On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.\u00a0 In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: \u2026 Continue reading \u2192 The post FDASIA, Part 3: Generating Antibiotic Incentives Now (GAIN) and Drug Approval and Patient Access Changes appeared first on Ask Cato ."], "link": "http://feedproxy.google.com/~r/AskCato/~3/2D7Yp0l7zrc/", "bloglinks": {}, "links": {"http://www.ask-cato.com": 1, "http://www.ask-cato.com/": 2}, "blogtitle": "Ask Cato"}]